{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:50:48Z","timestamp":1791355848250,"version":"4.3.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,12,7]],"date-time":"2015-12-07T00:00:00Z","timestamp":1449446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1038\/leu.2015.313","type":"journal-article","created":{"date-parts":[[2015,12,7]],"date-time":"2015-12-07T02:57:21Z","timestamp":1449457041000},"page":"929-936","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":237,"title":["A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study"],"prefix":"10.1038","volume":"30","author":[{"name":"on behalf of ERIC (European Research Initiative on CLL)","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A C","family":"Rawstron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Fazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Agathangelidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Villamor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Letestu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Nomdedeu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Palacio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Stehlikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K-A","family":"Kreuzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Liptrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R M","family":"de Tute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Marinov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Hauwel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Spacek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Dobber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A P","family":"Kater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Gambell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Soosapilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Lozanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Brachtl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Boysen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J L","family":"Jorgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Stetler-Stevenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H E","family":"Broome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Rassenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Craig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Egle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Doubek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Pospisilova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Mulligan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Westerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C M","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Emerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H S","family":"Robins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Kirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Shanafelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Pettitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T J","family":"Kipps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W G","family":"Wierda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Cymbalista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Hallek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Hillmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Montserrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Ghia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,12,7]]},"reference":[{"key":"BFleu2015313_CR1","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","volume":"376","author":"M Hallek","year":"2010","unstructured":"Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010; 376: 1164\u20131174.","journal-title":"Lancet"},{"key":"BFleu2015313_CR2","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1200\/JCO.2005.11.932","volume":"23","author":"E Montserrat","year":"2005","unstructured":"Montserrat E . Treatment of chronic lymphocytic leukemia: achieving minimal residual disease-negative status as a goal. J Clin Oncol 2005; 23: 2884\u20132885.","journal-title":"J Clin Oncol"},{"key":"BFleu2015313_CR3","unstructured":"Research C for DE and News & Events\u2014Public Workshop on Minimal Residual Disease (MRD) as a Surrogate Endpoint in Chronic Lymphocytic Leukemia (CLL). \n                    http:\/\/www.fda.gov\/Drugs\/NewsEvents\/ucm340707.htm\n                    \n                   (accessed 2 February 2015)."},{"key":"BFleu2015313_CR4","unstructured":"Guideline on the use of minimal residue disease as an endpoint in chronic lymphocytic leukaemia studies. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2014\/12\/WC500179047.pdf\n                    \n                   (accessed 3 February 2015)."},{"key":"BFleu2015313_CR5","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1200\/JCO.2011.36.9348","volume":"30","author":"S B\u00f6ttcher","year":"2012","unstructured":"B\u00f6ttcher S, Ritgen M, Fischer K, Stilgenbauer S, Busch RM, Fingerle-Rowson G et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol 2012; 30: 980\u2013988.","journal-title":"J Clin Oncol"},{"key":"BFleu2015313_CR6","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.1200\/JCO.2005.04.021","volume":"23","author":"P Moreton","year":"2005","unstructured":"Moreton P, Kennedy B, Lucas G, Leach M, Rassam SMB, Haynes A et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005; 23: 2971\u20132979.","journal-title":"J Clin Oncol"},{"key":"BFleu2015313_CR7","doi-asserted-by":"publisher","first-page":"4563","DOI":"10.1182\/blood-2005-09-3634","volume":"107","author":"C Moreno","year":"2006","unstructured":"Moreno C, Villamor N, Colomer D, Esteve J, Gin\u00e9 E, Munta\u00f1ola A et al. Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. Blood 2006; 107: 4563\u20134569.","journal-title":"Blood"},{"key":"BFleu2015313_CR8","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1182\/blood-2013-11-538116","volume":"123","author":"P Strati","year":"2014","unstructured":"Strati P, Keating MJ, O\u2019Brien SM, Burger J, Ferrajoli A, Jain N et al. Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. Blood 2014; 123: 3727\u20133732.","journal-title":"Blood"},{"key":"BFleu2015313_CR9","doi-asserted-by":"publisher","first-page":"873","DOI":"10.3324\/haematol.2013.099796","volume":"99","author":"R Santacruz","year":"2014","unstructured":"Santacruz R, Villamor N, Aymerich M, Mart\u00ednez-Trillos A, L\u00f3pez C, Navarro A et al. The prognostic impact of minimal residual disease in patients with chronic lymphocytic leukemia requiring first-line therapy. Haematologica 2014; 99: 873\u2013880.","journal-title":"Haematologica"},{"key":"BFleu2015313_CR10","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1182\/blood-2013-11-535047","volume":"123","author":"JR Brown","year":"2014","unstructured":"Brown JR, Byrd JC, Coutre SE, Benson DM, Flinn IW, Wagner-Johnston ND et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110\u03b4, for relapsed\/refractory chronic lymphocytic leukemia. Blood 2014; 123: 3390\u20133397.","journal-title":"Blood"},{"key":"BFleu2015313_CR11","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1400376","volume":"371","author":"JC Byrd","year":"2014","unstructured":"Byrd JC, Brown JR, O\u2019Brien S, Barrientos JC, Kay NE, Reddy NM et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014; 371: 213\u2013223.","journal-title":"N Engl J Med"},{"key":"BFleu2015313_CR12","unstructured":"FLAIR | CTRU Leeds. \n                    http:\/\/ctru.leeds.ac.uk\/flair\n                    \n                   (accessed 2 February 2015)."},{"key":"BFleu2015313_CR13","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1038\/sj.leu.2404584","volume":"21","author":"AC Rawstron","year":"2007","unstructured":"Rawstron AC, Villamor N, Ritgen M, B\u00f6ttcher S, Ghia P, Zehnder JL et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 2007; 21: 956\u2013964.","journal-title":"Leukemia"},{"key":"BFleu2015313_CR14","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/leu.2012.216","volume":"27","author":"AC Rawstron","year":"2013","unstructured":"Rawstron AC, B\u00f6ttcher S, Letestu R, Villamor N, Fazi C, Kartsios H et al. Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL. Leukemia 2013; 27: 142\u2013149.","journal-title":"Leukemia"},{"key":"BFleu2015313_CR15","doi-asserted-by":"publisher","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","volume":"111","author":"M Hallek","year":"2008","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, D\u00f6hner H et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111: 5446\u20135456.","journal-title":"Blood"},{"key":"BFleu2015313_CR16","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/ijlh.12149","volume":"36","author":"O Stehl\u00edkov\u00e1","year":"2014","unstructured":"Stehl\u00edkov\u00e1 O, Chovancov\u00e1 J, Tich\u00fd B, Krej\u010d\u00ed M, Brychtov\u00e1 Y, Panovsk\u00e1 A et al. Detecting minimal residual disease in patients with chronic lymphocytic leukemia using 8-color flow cytometry protocol in routine hematological practice. Int J Lab Hematol 2014; 36: 165\u2013171.","journal-title":"Int J Lab Hematol"},{"key":"BFleu2015313_CR17","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1002\/cyto.b.21067","volume":"84","author":"MM Sartor","year":"2013","unstructured":"Sartor MM, Gottlieb DJ . A single tube 10-color flow cytometry assay optimizes detection of minimal residual disease in chronic lymphocytic leukemia. Cytometry B Clin Cytom 2013; 84: 96\u2013103.","journal-title":"Cytometry B Clin Cytom"},{"key":"BFleu2015313_CR18","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1038\/leu.2013.52","volume":"27","author":"AC Logan","year":"2013","unstructured":"Logan AC, Zhang B, Narasimhan B, Carlton V, Zheng J, Moorhead M et al. Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia. Leukemia 2013; 27: 1659\u20131665.","journal-title":"Leukemia"},{"key":"BFleu2015313_CR19","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/cyto.b.21108","volume":"84","author":"B Wood","year":"2013","unstructured":"Wood B, Jevremovic D, B\u00e9n\u00e9 MC, Yan M, Jacobs P, Litwin V et al. Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS\u2014part V\u2014assay performance criteria. Cytometry B Clin Cytom 2013; 84: 315\u2013323.","journal-title":"Cytometry B Clin Cytom"},{"key":"BFleu2015313_CR20","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1182\/blood-2004-07-2606","volume":"105","author":"P Ghia","year":"2005","unstructured":"Ghia P, Stamatopoulos K, Belessi C, Moreno C, Stella S, Guida G et al. Geographic patterns and pathogenetic implications of IGHV gene usage in chronic lymphocytic leukemia: the lesson of the IGHV3-21 gene. Blood 2005; 105: 1678\u20131685.","journal-title":"Blood"},{"key":"BFleu2015313_CR21","doi-asserted-by":"publisher","first-page":"4521","DOI":"10.1182\/blood-2012-12-471698","volume":"121","author":"A Vardi","year":"2013","unstructured":"Vardi A, Dagklis A, Scarf\u00f2 L, Jelinek D, Newton D, Bennett F et al. Immunogenetics shows that not all MBL are equal: the larger the clone, the more similar to CLL. Blood 2013; 121: 4521\u20134528.","journal-title":"Blood"},{"key":"BFleu2015313_CR22","doi-asserted-by":"publisher","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","volume":"112","author":"S Branford","year":"2008","unstructured":"Branford S, Fletcher L, Cross NCP, M\u00fcller MC, Hochhaus A, Kim D-W et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood 2008; 112: 3330\u20133338.","journal-title":"Blood"},{"key":"BFleu2015313_CR23","first-page":"17","volume":"4","author":"M-P Lefranc","year":"2004","unstructured":"Lefranc M-P, Giudicelli V, Ginestoux C, Bosc N, Folch G, Guiraudou D et al. IMGT-ONTOLOGY for immunogenetics and immunoinformatics. In Silico Biol 2004; 4: 17\u201329.","journal-title":"In Silico Biol"},{"issue":"Suppl 1","key":"BFleu2015313_CR24","doi-asserted-by":"publisher","first-page":"i379","DOI":"10.1093\/bioinformatics\/bth945","volume":"20","author":"M Yousfi Monod","year":"2004","unstructured":"Yousfi Monod M, Giudicelli V, Chaume D, Lefranc M-P . IMGT\/JunctionAnalysis: the first tool for the analysis of the immunoglobulin and T cell receptor complex V-J and V-D-J JUNCTIONs. Bioinforma Oxf Engl 2004; 20 (Suppl 1): i379\u2013i385.","journal-title":"Bioinforma Oxf Engl"},{"key":"BFleu2015313_CR25","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1038\/leu.2012.120","volume":"26","author":"JJM van Dongen","year":"2012","unstructured":"van Dongen JJM, Lhermitte L, B\u00f6ttcher S, Almeida J, van der Velden VHJ, Flores-Montero J et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 2012; 26: 1908\u20131975.","journal-title":"Leukemia"},{"key":"BFleu2015313_CR26","first-page":"1640","volume":"8","author":"E Matutes","year":"1994","unstructured":"Matutes E, Owusu-Ankomah K, Morilla R, Garcia Marco J, Houlihan A, Que TH et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 1994; 8: 1640\u20131645.","journal-title":"Leukemia"},{"key":"BFleu2015313_CR27","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1158\/1078-0432.CCR-07-1823","volume":"14","author":"S Baskar","year":"2008","unstructured":"Baskar S, Kwong KY, Hofer T, Levy JM, Kennedy MG, Lee E et al. Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia. Clin Cancer Res 2008; 14: 396\u2013404.","journal-title":"Clin Cancer Res"},{"key":"BFleu2015313_CR28","doi-asserted-by":"publisher","first-page":"e273","DOI":"10.1038\/bcj.2014.92","volume":"5","author":"TW Farren","year":"2015","unstructured":"Farren TW, Giustiniani J, Fanous M, Liu F, Macey MG, Wright F et al. Minimal residual disease detection with tumor-specific CD160 correlates with event-free survival in chronic lymphocytic leukemia. Blood Cancer J 2015; 5: e273.","journal-title":"Blood Cancer J"},{"key":"BFleu2015313_CR29","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1038\/leu.2009.140","volume":"23","author":"S B\u00f6ttcher","year":"2009","unstructured":"B\u00f6ttcher S, Stilgenbauer S, Busch R, Br\u00fcggemann M, Raff T, Pott C et al. Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis. Leukemia 2009; 23: 2007\u20132017.","journal-title":"Leukemia"},{"key":"BFleu2015313_CR30","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1182\/blood.V98.1.29","volume":"98","author":"AC Rawstron","year":"2001","unstructured":"Rawstron AC, Kennedy B, Evans PA, Davies FE, Richards SJ, Haynes AP et al. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 2001; 98: 29\u201335.","journal-title":"Blood"},{"key":"BFleu2015313_CR31","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1038\/sj.leu.2404416","volume":"20","author":"AC Rawstron","year":"2006","unstructured":"Rawstron AC, de Tute R, Jack AS, Hillmen P . Flow cytometric protein expression profiling as a systematic approach for developing disease-specific assays: identification of a chronic lymphocytic leukaemia-specific assay for use in rituximab-containing regimens. Leukemia 2006; 20: 2102\u20132110.","journal-title":"Leukemia"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/leu2015313.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/leu2015313","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/leu2015313.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T14:05:20Z","timestamp":1684418720000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2015313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,7]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["BFleu2015313"],"URL":"https:\/\/doi.org\/10.1038\/leu.2015.313","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,7]]},"assertion":[{"value":"8 May 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The type of relationship with the organizations are: ACR: Celgene, Honoraria; BD Biosciences, royalty payments (Intrasure reagent) and study reagents; Abbvie, Honoraria; Gilead, Consultancy and Honoraria; Biogen Idec, Consultancy; Roche, Honoraria; and GSK, Honoraria. PG: AbbVie, Honoraria; Adaptive Biotechnologies, Consultancy; Celgene, Consultancy; Gilead, Consultancy, Honoraria and research funds; GSK, research funds; Janssen, Consultancy and Honoraria; Pharmacyclics, Consultancy; and Roche, Research funds. All other co-authors report no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}